EMYRIA LIMITED — Director's Dealing 2020

Nov 15, 2020

ASX/Media Release

==> picture [116 x 62] intentionally omitted <==

16/11/2020

Change of Director’s Interest Notice

Emyria Limited (ASX: EMD) (“Emyria” or “the Company”), a company that accelerates treatment development for patients with unmet needs, is pleased to advise that Chairman, Stewart Washer, has made various on-market purchases of shares in the Company.

A Change of Director’s Interest Notice is annexed to this announcement.

Emyria’s Chairman, Dr Stewart Washer , said: “It is an exciting and transformational period for Emyria. Medicine is evolving rapidly with digital health but there’s a constant need for new, safe and effective treatments. Emyria is ahead of the pack in treating patients who have been sick for a long time and are not getting better with current care. We do this by using innovative treatments, like cannabinoids, and by using digital health technologies. Emyria can monitor patients, collect evidence and contribute to improving these new treatments. I’m highly optimistic about the path ahead for Emyria, and look forward to rolling out our products and technologies globally into 2021.”

Emyria’s Managing Director, Dr Michael Winlo, said: “Dr Washer is a respected executive, leader and investor and his most recent purchase of additional shares is a strong endorsement of our team, our work and our future potential. Emyria is fortunate to be backed by a great Board on our quest to bring innovative new treatments to patients sooner while also delivering value for our shareholders.”

Release authorised by: Stewart Washer Chairman

For further information

Dr Michael Winlo Lexi O’Halloran Managing Director Media/Investor Relations (08) 6559 2800 + 61 (0) 404 577 076 mwinlo@emyria.com lexi@janemorganmanagement.com.au

About Emyria (www.emyria.com)

Emyria Limited creates clinical evidence that accelerates the development of new treatments for patients with unmet needs. Emyria achieves this by analysing the high quality clinical data gathered from its specialist clinical network – Emerald Clinics (www.emeraldclinics.com.au) – and turning that into Real-World Evidence (RWE). Emyria’s data supports the development and registration of new and promising treatments for patients with unmet medical needs by providing unique, real-world insights into the safety, quality and efficacy of those unapproved treatments, in real patients in the community. Emyria’s data assets are also a source of unique IP for Emyria, which along with its remote patient monitoring technologies, data platforms and care models, further improve the quality of its RWE data assets and insights as well as the care provided to patients.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability

==> picture [592 x 41] intentionally omitted <==

to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.s

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and made be made public.

Introduced 30/09/2001

Name of entity:	Emerald Clinics Limited
ABN:	625 085 734

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

director for the purposes	of section 205G of the Corporations Act.
Name of Director:	Stewart Washer
Date of last notice:	17/03/2020

Part 1 - Change of director’s relevant interests in securities

Note: In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust. In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> (Dr Washer is a trustee and beneficiary of the superannuation fund) Dr Stewart James Washer & Dr Patrizia Derna Washer (Dr Washer is a trustee and beneficiary of the Trust) Mal Washer Nominees Pty Ltd Family A/C> (Dr Washer is a trustee and beneficiary of the trust)
Date of change	09/11/2020 10/11/2020 11/11/2020 12/11/2020
No. of securities held prior to change
Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> (Dr Washer is a trustee and beneficiary of the superannuation fund) Dr Stewart James Washer & Dr Patrizia Derna Washer (Dr Washer is a trustee and beneficiary of the Trust)	550,599 Ordinary Shares( +100 shares correction) 28,400,000 Ordinary Shares 1,500,000 Unlisted Options exercisable at $0.45 expiring 13 June 2023

• See chapter 19 for defined terms

Appendix 3Y pg. 1

Appendix 3Y Change of Director’s Interest Notice

	Appendix 3Y Change of Director’s Interest Notice
Mal Washer Nominees Pty Ltd Family A/C> (Dr Washer is a trustee and beneficiary of the trust)	19,600,000 Ordinary Shares
Class changed	Ordinary Shares
Number acquired	270,000 100,000 150,000 255,000
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$20,765.65 $7,986.90 $12,283.65 $20,321.22
No. of securities held after change
Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> (Dr Washer is a trustee and beneficiary of the superannuation fund) Dr Stewart James Washer & Dr Patrizia Derna Washer (Dr Washer is a trustee and beneficiary of the Trust) Mal Washer Nominees Pty Ltd Family A/C> (Dr Washer is a trustee and beneficiaryof the trust)	1,325,599 Ordinary Shares 28,400,000 Ordinary Shares 1,500,000 Unlisted Options exercisable at $0.45 expiring 13 June 2023 19,600,000 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market purchases

Part 2 - Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: if consideration is non-cash, provide details and an estimated valuation	N/A

• See chapter 19 for defined terms

Appendix 3Y pg. 2

Appendix 3Y Change of Director’s Interest Notice

		Appendix 3Y Change of Director’s Interest Notice
Interest after changes		N/A
Part 3 – Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms

Appendix 3Y pg. 3